BEFORE THE
OREGON MEDICAL BOARD
STATE OF OREGON

In the Matter of
JOHN EDWIN GAMBEE, MD
LICENSE NO. MD09526

INTERIM STIPULATED ORDER

1.
The Oregon Medical Board (Board) is the state agency responsible for licensing,
regulating and disciplining certain health care providers, including physicians, in the state of
Oregon. John Edwin Gambee, MD (Licensee) is a licensed physician in the state of Oregon and
holds an active medical license.

2.
Licensee is required to practice medicine in a manner consistent with the terms of a
Stipulated Order that was approved on April 1, 1997. This Order was revised by an Order
Modifying the Stipulated Order, dated January 1, 2004. Paragraph 5.5 of the Order Modifying
the Stipulated Order requires Licensee to comply with the following practice limitations:

Licensee shall use thyroid function blood tests (with appropriate documentation in the
patient charts), to include blood tests that measure the amount of thyroid hormone (free
T4) and thyroid-stimulating hormone (TSH) in conjunction with the history and physical
findings in making the decision whether to use thyroid medication. Licensee will not use
thyroid medication in treatment unless the blood tests find a TSH level greater than the
normal range and a free T4 below the normal range on a test. While treating patients with
thyroid medication, Licensee shall periodically retest the TSH level of his patients’ blood
no later than six weeks after initiating treatment with thyroid medication and no less than

///
annually thereafter. Licensee shall reduce the level of thyroid medication if the level of TSH falls below the normal range.

3.

The Board has opened an investigation into allegations that Licensee may have practiced medicine in a manner that violated the terms of the Stipulated Order and Order Modifying the Stipulated Order. Licensee submitted a letter to the Board dated February 5, 2010, proposing that he practice medicine in conformity to certain limitations. In order to address the Board's concern, Licensee and the Board agree to the entry of this Interim Stipulated Order, which will remain in effect while this matter remains under investigation, and provides that Licensee shall comply with the following conditions:

3.1 Licensee will not recommend, prescribe, or direct any patient to take thyroid unless patient TSH levels exceed 10 uIU/mL, except that Licensee may recommend, prescribe or direct a patient to take thyroid supplementation if patient TSH levels are between 5 and 10 uIU/mL and the patient has also been diagnosed with goiter or positive anti-thyroid peroxidase antibodies (or both).

3.2 Licensee will require any patient taking thyroid from a non-prescription source to undergo thyroid blood tests on a regular basis (at least every 6 months) and that Licensee will direct such patients to adjust their dose to bring their TSH level into the range recommended by the American Association of Clinical Endocrinologists (AACE) (the target TSH level is between 0.3 and 3.0 uIU/mL). If any patient declines to follow this direction, Licensee will provide 30 day prior written notice to the patient and then terminate the physician – patient relationship.

3.3 In the event Licensee decides to prescribe, recommend, direct a patient to take testosterone, or to follow a patient taking testosterone, Licensee must comply with the guidelines recommended in the article “Risks of Testosterone Replacement Therapy and Recommendations for Monitoring,” published in the New England
Journal of Medicine, 350:5, January 29, 2004. Specifically, Licensee will ensure that either he or another physician has conducted and documented a recent digital rectal examination and that at a minimum, blood tests for baseline testosterone and PSA levels have been performed. Licensee must not prescribe, recommend, or direct a patient to take testosterone for patients with a PSA level above 4.0 ng/mL as well as patients with a yearly PSA increase of 1.5 ng/mL or more, or 0.75 ng/mL per year or more over two years. If any patient insists that they want to take testosterone in the face of such PSA levels, Licensee will provide 30 day prior written notice to the patient and then terminate the physician – patient relationship.

3.4 Licensee must make appropriate and timely chart entries to demonstrate that he is complying with the terms of this Order.

3.5 Licensee’s practice is subject to no notice compliance inspections by Board staff.

3.6 Licensee understands that violating any term of this Order will be grounds for disciplinary action under ORS 677.190(17).

3.7 Licensee understands this Order becomes effective the date this Order is signed by the Board Chair.

4.

At the conclusion of the Board’s investigation, the Board will decide whether to close the case or to proceed to some form of disciplinary action. If the Board determines, following that review, that this limitation of license shall not be lifted, Licensee may request a hearing to contest that decision.

5.

This order is issued by the Board pursuant to ORS 677.410, which grants the Board the authority to attach conditions to the license of Licensee to practice medicine. These conditions will remain in effect while the Board conducts a complete investigation in order to fully inform itself with respect to the conduct of Licensee. Pursuant to ORS 676.175, Board investigative materials are confidential and shall not be subject to public disclosure, nor shall they
be admissible as evidence in any judicial proceeding. However, as a stipulation this Order is a
public record and is a disciplinary action that is reportable to the National Practitioner Data Bank,
Healthcare Integrity and Protection Data Bank and the Federation of State Medical Boards.

IT IS SO STIPULATED THIS 18 day of MARCH, 2010.

Signature Redacted on Copies

JOHN EDWIN GAMBEE, MD

IT IS SO ORDERED THIS 18th day of MARCH, 2010.

OREGON MEDICAL BOARD
State of Oregon

Signature Redacted on Copies

KATHLEEN HALEY, JD
Executive Director